News and Events

Registration now open for Frontiers in Light Microscopy

The Frontiers in Light Microscopy conference is a platform to discuss the latest advances in microscopy and biological imaging. The current state of the art in light microscopy will be presented by leading researchers in the field who will cover topics such as intravital imaging, super-resolution microscopy and light sheet microscopy. Sessions will include organelle dynamics and function, multicellular organisms and imaging the immune system.

Clinical trial tests a new drug therapy for recurrent ependymomas of the brain and spinal cord

Ependymomas are rare tumors that arise in the ependyma, the thin membrane that lines fluid-filled cavities in the brain and spinal cord, and there are limited treatment options for those that have already been treated with standard therapies. A new clinical trial is testing a drug that targets ependymomas that have a specific genetic signature.

Nataliya Buxbaum wins Magnetic Moments video competition

Nataliya P. Buxbaum, M.D., Assistant Clinical Investigator in the Experimental Transplantation and Immunology Branch, was named the overall winner of the International Society for Magnetic Resonance in Medicine’s Magnetic Moments Competition. The competition is designed for investigators to use video to describe their MRI-related research for a general audience. Dr. Buxbaum’s video describes her research using tracers to better and more safely image tumors.

Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer

Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC.

Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer

A new clinical trial at the NCI’s Center for Cancer Research is set to explore if eliminating certain bacteria in the gut will boost the immune system response in patients who have hepatocellular carcinoma and liver metastases.

Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers

Julius Strauss, M.D., Assistant Research Physician in the Laboratory of Tumor Immunology and Biology, discussed a promising immunotherapy drug for patients with HPV-related cancers in a recent NCI Cancer Currents blog post. According to results from a phase 1 clinical trial, 33 percent of the 36 patients on the trial with HPV-positive tumors responded to the drug, and four of the responses lasted longer than 18 months. “This drug is a promising agent for patients with HPV-related cancers and may potentially benefit these patients more than traditional checkpoint therapies,” said Dr. Strauss.

Brid Ryan cohosts NCI Minority Health Month Facebook Live

The National Cancer Institute hosted a Facebook Live entitled, “A Dialogue on Cancer Disparities, Prevention, and Research.”The event featured Brid M. Ryan, Ph.D., M.P.H., Investigator in the Laboratory of Human Carcinogenesis, as well as Worta McCaskill-Stevens, M.D., M.S., from the Division of Cancer Prevention, and Christina Dieli-Conwright, Ph.D., M.P.H., from the University of Southern California. They discussed cancer disparities and the work being done to help reduce them.

A patient’s 10-year journey to moxetumomab for hairy cell leukemia

Randy, a father, husband, engineering quality consultant and lifelong “Motor City” resident, was diagnosed with hairy cell leukemia in 1998 at the age of 41. After participation in a clinical trial at the NIH Clinical Center, his body has shown a complete response to the drug moxetumomab pasudotox, which was developed at the National Cancer Institute’s Center for Cancer Research.

Photomicrograph showing graft-versus-host disease in the skin

Cyclophosphamide works in an unexpected way to curb graft-vs-host disease in mice

For years it has been assumed that cyclophosphamide helps reduce the severity of graft-versus-host disease by eliminating alloreactive T cells, but new evidence reveals a different reason.

Marston Linehan receives 2019 Urology Care Foundation Distinguished Mentor award

Marston Linehan, M.D., Chief of the Urologic Oncology Branch, has received the 2019 Urology Care Foundation Distinguished Mentor award. The award recognizes Dr. Linehan’s outstanding track record of fostering the next generation of urologic researchers by providing excellent training and guidance to early-career investigators.

Breadcrumb